Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX · NASDAQ Global Market
+$0.01 today
Vol 0.59M · Avg 0.22M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:EPRX · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$42.5M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.00, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $331.9K +103.0% | $163.5K | $0 | $0 -100.0% | $112.4K | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$331.9K -103.0% | -$163.5K | $0 | $0 +100.0% | -$112.4K | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $29.5M +83.6% | $16.1M +4.8% | $15.3M +12.5% | $13.6M +79.6% | $7.6M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $17.1M +56.7% | $10.9M +93.7% | $5.6M +41.3% | $4.0M -42.8% | $7.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $53.3M +97.6% | $27.0M +28.7% | $21.0M +19.0% | $17.6M +20.3% | $14.6M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $331.9K +93.4% | $171.6K +46.5% | $117.1K -20.8% | $147.9K +69.1% | $87.5K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$53.3M -113.7% | -$25.0M -20.0% | -$20.8M -16.4% | -$17.9M -3.7% | -$17.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$53.7M -98.8% | -$27.0M -28.7% | -$21.0M -19.0% | -$17.6M -20.3% | -$14.6M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.4M +21.9% | $1.2M +78.4% | $649.8K +50.5% | $431.8K +737.6% | $51.5K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 -100.0% | $603.2K -31.5% | $881.1K -10.4% | $982.9K -3.4% | $1.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$212.9K -116.9% | $1.3M +254.6% | -$814.9K +40.7% | -$1.4M +62.7% | -$3.7M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$53.9M -109.4% | -$25.7M -18.1% | -$21.8M -14.7% | -$19.0M -3.6% | -$18.3M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $26.7K +1379.1% | $1.8K -93.4% | $27.4K | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$53.9M -111.3% | -$25.5M -19.9% | -$21.2M -14.9% | -$18.5M -2.5% | -$18.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 -38.2% | -$1 +13.6% | -$1 +8.3% | -$1 +41.1% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 -38.2% | -$1 +13.6% | -$1 +8.3% | -$1 +41.1% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $40.0M +17.8% | $33.9M +40.5% | $24.1M +25.2% | $19.3M +35.4% | $14.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $40.0M +17.8% | $33.9M +40.5% | $24.1M +25.2% | $19.3M +35.4% | $14.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
$1.12B
Genfit S.A.
GNFT
$445.68M
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
$284.66M
Cartesian Therapeutics, Inc.
NASDAQ:RNAC
$279.42M
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
$245.51M
Inventiva S.A.
NASDAQ:IVA
$200.13M
MediWound Ltd.
NASDAQ:MDWD
$154.46M
Protara Therapeutics, Inc.
NASDAQ:TARA
$150.50M
Neonc Technologies Holdings, Inc.
NASDAQ:NTHI
$94.98M
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
$85.08M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does EPRX generate?
Eupraxia Pharmaceuticals Inc. (EPRX) reported $0.00 of revenue in fiscal 2025.
Is EPRX profitable?
Eupraxia Pharmaceuticals Inc. (EPRX) reported -$53,858,075.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.